event details

BridgeBio Pharma to Discuss Phase 2 Data for BBP-418 in Limb-Girdle Muscular Dystrophy Type 2i (LGMD2i)

Print Page

Email Alerts

RSS Feeds

Contact IR

Stay informed on everything that is happening at BridgeBio Investor Relations.

Required fields denoted by an asterisk ().

3160 Porter Drive, Suite 250, Palo Alto, CA, 94304 | 650-391-9740 | info@bridgebio.com | MAT-AS—0001